It was the year of drug pricing, fantasy-sports and Uber regulations, and countless cyber and terror attacks. It was a year when initial public offerings were few and far between for technology companies, and the biotech window may have closed as well. Yet there were plenty of commercial advances in fields like gene editing, immunotherapy, artificial intelligence, virtual reality, and 3D printing.
Image: http://www.xconomy.com
